Arvinas, Inc.

Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update

– Initiated dosing in a Phase 1/2 trial of ARV-6723, an immuno-oncology oral PROTAC designed to degrade HPK1, a negative regulator of immune…